AtriCure Reports Second Quarter 2026 Financial Results
AtriCure, Inc. announced their financial results for the second quarter of 2026, showcasing healthy growth and increased profitability. CEO Michael Carrel highlighted the success of their innovative technologies in surgical treatments for atrial fibrillation and related areas.
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu